Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Transcatheter Tricuspid Edge-to-Edge Repair: a real-world single-center experience
Session:
Sessão de Posters 30 - Intervenções valvulares cirúrgicas e transcateter para além da válvula aórtica
Speaker:
Márcia Presume
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
15. Valvular Heart Disease
Subtheme:
15.4 Valvular Heart Disease – Treatment
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Márcia Presume; Catarina Santos-Jogre; Samuel Azevedo; Rita Barbosa; Margarida Matias; Paula Ratinho; Marisa Trabulo; Pedro Araújo Gonçalves; Eduardo Infante de Oliveira; Regina Ribeiras; Rui Campante Teles; Manuel de Sousa Almeida
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">Background:</span></span></span></strong><span style="font-size:10.0pt"><span style="background-color:white"><span style="font-family:"Arial","sans-serif""><span style="color:black"> Severe tricuspid regurgitation (TR) is </span></span></span><span style="font-family:"Arial","sans-serif""><span style="color:black">a challenging condition with <span style="background-color:white">high morbidity, </span>particularly in advanced stages. T</span></span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black"><span style="background-color:white">ranscatheter tricuspid edge-to-edge repair (T-TEER) has emerged as a therapeutic option for patients at high surgical risk.</span></span></span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black"><span style="background-color:white"><strong> </strong>We aimed to describe the baseline profile, procedural characteristics, safety, and mid-term clinical outcomes of patients undergoing T-TEER.</span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">Methods:</span></span></span></strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black"> We conducted a single-center retrospective analysis of consecutive patients who underwent T-TEER between 2021 and 2025 at our center. Baseline clinical, echocardiographic, and procedural data were collected. Outcomes were assessed at discharge, 6 months and 1 year, including functional status, heart-failure rehospitalizations, and mortality.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">Results: </span></span></span></strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">A total of 35 patients were included (mean age 80±4 years; 74.3% female). Most patients were highly symptomatic (NYHA class III–IV in 68.6%), and presented a high comorbidity burden, including atrial fibrillation (97.1%), hypertension (71.4%), dyslipidemia (51.4%), diabetes mellitus (37.1%) and chronic kidney disease (22.9%). Regarding prior cardiac interventions, 37.1% patients had a history of left-sided valve surgery. All patients were on chronic oral anticoagulation, and 91.4% on loop diuretics. Median NT-proBNP was 1877pg/mL [1177-2708], and the median TRI-SCORE was 4 (range 2–9).</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">TR was predominantly secondary (88.6%), mainly due to annular dilation (62.9%), and was classified as severe, massive or torrential in 40%, 20% and 40% of patients, respectively. Right ventricular (RV) dysfunction was present in 28.6%, with atrial and ventricular dilation in 97.1% and 80% of patients, respectively. Right heart catheterization, performed in 45.7%, showed predominantly mild precapillary and combined pulmonary hypertension.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">Most procedures were elective (80%), with a median hospital stay of 2 days [1-10]. The PASCAL system was used in 68.6% of procedures, with a median of 2 devices per patient. A reduction of at least two grades in TR severity was achieved in 57.2% of patients, with residual TR less than or equal to moderate in 68.5%. </span></span></span><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif"">Partial device detachment occurred in 17.1%, and RV dysfunction was documented in 22.9%. Bleeding complications, for any cause, occurred in 8.6%.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">At 6 months, 77.1% reported symptomatic improvement, with 71.4% in NYHA class I–II. Heart failure readmissions occurred in 17.1%. Overall mortality was 20%, with a 30-day mortality of 5.7% and 1-year mortality of 14.3%. </span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">Conclusions: </span></span></span></strong><span style="font-size:10.0pt"><span style="font-family:"Arial","sans-serif""><span style="color:black">In this cohort, T-TEER was associated with symptomatic improvement and acceptable mid-term outcomes. These findings reinforce T-TEER as a feasible and effective therapeutic option in carefully selected patients, although larger studies with longer follow-up are needed.</span></span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site